No-cost study-related care under a doctor’s supervision for a 6 month research study

New research opportunity for dementia: investigational treatment targeting inflammation

See if you qualify

Fill out the form below to see if you meet the basic study requirements. If you are filling this out on behalf of a friend or loved-one, please enter the information on their behalf but please include YOUR contact phone number for follow up.

What do I need to know?

  • Once you complete the form, you will receive a call from the study staff to answer further qualification questions and schedule your first visit.
  • Study visits will be once per week during the 24-week treatment period to receive the investigational treatment or a placebo (Important notes: Twice as many patients will receive the investigational treatment than those that will receive placebo)
  • Stay engaged with the study by attending a follow-up phone call 28 days after your last visit to assess your progress.
  • All eligible participants will receive an opportunity to receive the study drug for up to an additional 12 months after conclusion of the six-month study, regardless of whether they were receiving the study drug during the 24-week treatment period or not.

Frequently asked questions

Where is this study located?

This study has locations across multiple cities in Australia.

What is the goal of the study?

The goal of this AD study is to determine if the investigational study medication is effective at either improving or slowing disease progression on measures of cognition, functioning and behavior in individuals with early Alzheimer’s disease with biomarkers of inflammation.

If I receive the placebo, will I be able to try the investigational study medication?

Yes, at the end of the full 24-week study period, all eligible participants will have the opportunity to receive the investigational study medication for one year.

How long is the study?

The study is approximately 33 weeks long, comprised of an up to 45-day screening period, a 24-week treatment period, and a 28-day follow-up period.

How does this study compare with other Dementia studies?

A notable difference in this study versus other investigational studies for Dementia is the short treatment period of 24 weeks. Additionally, the study requires only 9-13 study visits and the drug may be administered at home for a portion of the study period if the patient and/or caregiver prefers.

What is the study drug?

The study drug is called the XPRO1595 which is administered via a weekly injection.

I’m a caregiver or loved one of someone suffering with dementia, what do I need to know?

For this study, the enrolled patient is required to have a “study partner” in order to participate. The Study Partner must be knowledgeable about the patient’s behaviors, routines, and medications with the goal of assisting the participant in meeting study requirements, including co-attending study visits (as few as 9).